tetano
Editor, Senior Moderator
NPJ Vaccines
. 2020 Jul 9;5(1):57.
doi: 10.1038/s41541-020-0206-5.
Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection
Xiang Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Ping Zhou[SUP] #[/SUP][SUP] 3 4 [/SUP], Mangteng Wu[SUP] 3 4 [/SUP], Kaiyan Yang[SUP] 3 4 [/SUP], Jingao Guo[SUP] 3 4 [/SUP], Xuchen Wang[SUP] 3 4 [/SUP], Jun Li[SUP] 3 4 [/SUP], Zihao Fang[SUP] 3 4 [/SUP], Guiqin Wang[SUP] 3 [/SUP], Man Xing[SUP] 5 [/SUP], Dongming Zhou[SUP] 6 7 8 9 [/SUP]
Affiliations
Abstract
Due to the high mutation and recombination rates of the influenza virus, current clinically licensed influenza vaccines and anti-influenza drugs provide limited protection against the emerging influenza virus epidemic. Therefore, universal influenza vaccines with high efficacy are urgently needed to ensure human safety and health. Passive immunization of influenza broadly neutralizing antibodies may become an ideal option for controlling influenza infection. CR9114 isolated from the peripheral blood mononuclear cells of healthy donors is a broadly neutralizing monoclonal antibody that targets different types of influenza viruses. As the adenovirus vector is one of the most promising delivery vehicles, we employed the chimpanzee adenoviral vector, AdC68, to express CR9114 as a universal anti-influenza vaccine, termed AdC68-CR9114, and evaluated its antibody expression and its broad spectrum of prophylactic and therapeutic effects in animal models. Based on our findings, AdC68-CR9114-infected cell expressed the broadly neutralizing antibody at a high level in vitro and in vivo, exhibited biological functions, and protected mice from different types of influenza virus infection at different time points. The findings from this study shed light on a new strategy for controlling and preventing influenza infection
. 2020 Jul 9;5(1):57.
doi: 10.1038/s41541-020-0206-5.
Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection
Xiang Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Ping Zhou[SUP] #[/SUP][SUP] 3 4 [/SUP], Mangteng Wu[SUP] 3 4 [/SUP], Kaiyan Yang[SUP] 3 4 [/SUP], Jingao Guo[SUP] 3 4 [/SUP], Xuchen Wang[SUP] 3 4 [/SUP], Jun Li[SUP] 3 4 [/SUP], Zihao Fang[SUP] 3 4 [/SUP], Guiqin Wang[SUP] 3 [/SUP], Man Xing[SUP] 5 [/SUP], Dongming Zhou[SUP] 6 7 8 9 [/SUP]
Affiliations
- PMID: 33574338
- DOI: 10.1038/s41541-020-0206-5
Abstract
Due to the high mutation and recombination rates of the influenza virus, current clinically licensed influenza vaccines and anti-influenza drugs provide limited protection against the emerging influenza virus epidemic. Therefore, universal influenza vaccines with high efficacy are urgently needed to ensure human safety and health. Passive immunization of influenza broadly neutralizing antibodies may become an ideal option for controlling influenza infection. CR9114 isolated from the peripheral blood mononuclear cells of healthy donors is a broadly neutralizing monoclonal antibody that targets different types of influenza viruses. As the adenovirus vector is one of the most promising delivery vehicles, we employed the chimpanzee adenoviral vector, AdC68, to express CR9114 as a universal anti-influenza vaccine, termed AdC68-CR9114, and evaluated its antibody expression and its broad spectrum of prophylactic and therapeutic effects in animal models. Based on our findings, AdC68-CR9114-infected cell expressed the broadly neutralizing antibody at a high level in vitro and in vivo, exhibited biological functions, and protected mice from different types of influenza virus infection at different time points. The findings from this study shed light on a new strategy for controlling and preventing influenza infection